Clinical Trials 101 | Alzheimer's Prevention Registry

You are here

Clinical Trials 101

Alzheimer’s Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer’s Disease

The Alzheimer’s Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) and the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, which are currently being evaluated as treatments for early Alzheimer’s disease (AD), have been selected by the ACTC as treatments to be evaluated in upcoming clinical studies targeting primary prevention (A3 Study) and secondary prevention (A45 Study) of AD. These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai.

Biogen Ends Late-Stage Alzheimer’s Trials, Crushing Hopes and Calling Amyloid Into Question

Clinical trial participants, researchers and investors were reeling on Thursday after Biogen and Eisai, its Japanese pharmaceutical partner, announced that they would be halting two Stage 3 clinical trials that had previously reported positive results. Biogen said the drug, aducanumab, was unlikely to help patients.

An Alzheimer’s Drug Trial Gave Me Hope, and Then It Ended

I was a small piece in the search to find a cure. Now I feel as if I’m getting erased, and medical science doesn’t have any answers.

Failed Alzheimer’s trial leaves families and patients heartbroken. Medical community reels

Every month, a car would pick up Jeff Borghoff at his home in Forked River, New Jersey, and drive him to the Advanced Memory Research Institute of New Jersey. There, doctors would help him settle into a comfortable chair and hook him up to an IV.
 

2018—A Year in Research

Once again, it’s time to reflect on the preceding 12 months. Despite the 2025 deadline for effective therapy that has been set by the National Alzheimer’s Plan and the World Dementia Council, 2018 brought no drug approvals or Phase 3 breakthroughs. Short of that, however, smaller advances happened across neurodegenerative research this past year. 

National Recruitment Strategy Aims to Open Doors Wider to Participation in Research Studies

You may have heard of the ambitious goal set by the U.S. National Plan to Address Alzheimer’s Disease – to prevent and effectively treat Alzheimer’s disease by 2025. While this plan offers great promise, it also shines the spotlight on the need for volunteer research participants. 

Alzheimer's Stigma Hinders Research

Currently, several trials are trying to develop therapies for AD by 2025. These trials’ success, however, depends upon participants who are willing to undergo genetic and biomarker testing to learn if they are at risk of AD dementia. 

Blood Test Could Predict the Risk of Alzheimer's

Researchers hope the test will help with drug trials and early intervention

Inside One Couple’s Experimental Treatment to Battle Alzheimer’s Disease

Married for more than 50 years, the Woodings are among the more than 5 million Americans who are facing Alzheimer’s disease, one of the most devastating diagnoses today. But instead of accepting the slow descent into memory loss, confusion and dementia, Peter–who has the disease–could be among the first to successfully stop that decline from happening.

Merck Will End Alzheimer's Trial as Alternative Approach Fails

Merck & Co. will stop its final-stage test of an Alzheimer’s compound that was once seen as a promising alternative to other now-failed approaches.Merck & Co. will stop its final-stage test of an Alzheimer’s compound that was once seen as a promising alternative to other now-failed approaches.